Northern Trust Corp Has $5.61 Million Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Northern Trust Corp grew its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 11.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 283,599 shares of the company's stock after acquiring an additional 28,393 shares during the period. Northern Trust Corp owned 0.39% of Kiniksa Pharmaceuticals worth $5,610,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Oberweis Asset Management Inc. lifted its stake in shares of Kiniksa Pharmaceuticals by 18.0% in the 4th quarter. Oberweis Asset Management Inc. now owns 237,200 shares of the company's stock valued at $4,692,000 after acquiring an additional 36,200 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 16.8% in the 4th quarter. Voya Investment Management LLC now owns 19,988 shares of the company's stock valued at $395,000 after acquiring an additional 2,870 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Kiniksa Pharmaceuticals by 23.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,111 shares of the company's stock valued at $299,000 after acquiring an additional 2,881 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after acquiring an additional 4,575 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after acquiring an additional 1,374 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Price Performance

NASDAQ KNSA traded up $0.94 on Friday, reaching $26.89. The company had a trading volume of 590,247 shares, compared to its average volume of 487,154. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -192.06 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The business has a 50 day moving average of $23.26 and a two-hundred day moving average of $21.50.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same period last year, the business posted ($0.25) EPS. The business's revenue was up 72.5% compared to the same quarter last year. As a group, research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, insider Ross Moat sold 18,259 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the sale, the insider now directly owns 9,415 shares in the company, valued at approximately $191,030.35. This trade represents a 65.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 12,000 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $20.48, for a total value of $245,760.00. Following the sale, the chief operating officer now owns 77,363 shares of the company's stock, valued at approximately $1,584,394.24. The trade was a 13.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 243,640 shares of company stock worth $5,986,056. Company insiders own 54.57% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KNSA. Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective for the company. Finally, Wedbush restated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.